

# **UAB "Atelda"**

**COMPANY'S FINANCIAL INFORMATION FOR THE REPORTING PERIOD OF  
1 JANUARY 2022 - 31 MARCH 2022**

UAB "Atelda"

Company code 305682223, address Jogailos g. 4, Vilnius

COMPANY'S FINANCIAL INFORMATION AS OF THE 31 MARCH 2022

(all amounts are in EUR unless otherwise stated)

---

## Financial position

	31 March 2022	31 December 2021
<b>ASSETS</b>		
<b>A FIXED ASSETS</b>	-	-
I. Intangible assets	-	-
II. Tangible assets	-	-
III. Financial assets	-	-
IV. Other fixed assets	-	-
<b>B CURRENT ASSETS</b>	<b>2 497</b>	<b>2 500</b>
I. Stocks	-	-
II. Amounts receivable within one year	-	-
III. Short-term investments	-	-
IV. Cash and cash equivalents	2 497	2 500
<b>C PREPAYMENTS AND ACCRUED INCOME</b>	-	-
<b>TOTAL ASSETS</b>	<b>2 497</b>	<b>2 500</b>

UAB "Atelda"

Company code 305682223, address Jogailos g. 4, Vilnius

COMPANY'S FINANCIAL INFORMATION AS OF THE 31 MARCH 2022

(all amounts are in EUR unless otherwise stated)

## Financial position (continued)

	31 March 2022	31 December 2021
<b>EQUITY AND LIABILITIES</b>		
<b>D. EQUITY</b>	<b>2 073</b>	<b>2 500</b>
I. Capital	2 500	2 500
II. Share premium account	-	-
III. Revaluation reserve	-	-
IV. Reserves	-	-
V. Retained profit (loss)	(427)	-
<b>E. GRANTS, SUBSIDIES</b>	-	-
<b>F. PROVISIONS</b>	-	-
<b>G. AMOUNTS PAYABLE AND OTHER LIABILITIES</b>	-	-
I. Amounts payable after one year and other long-term liabilities	-	-
II. Amounts payable within one year and other short-term liabilities	-	-
<b>H. ACCRUALS AND DEFERRED INCOME</b>	<b>424</b>	<b>-</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>2 497</b>	<b>2 500</b>

Financial statements signed by electronic signature:

_____ General Manager	_____ Tomas Milašauskas
_____ Representative of a company providing accounting services	_____ Virginija Skirmantė

UAB "Atelda"

Company code 305682223, address Jogailos g. 4, Vilnius

COMPANY'S FINANCIAL INFORMATION AS OF THE 31 MARCH 2022

(all amounts are in EUR unless otherwise stated)

## Income Statement

	Notes	2022.01.01 - 2022.03.31	2021.01.01 - 2021.03.31
I. Net turnover		-	-
II. Cost of sales		-	-
III. Fair value adjustments of the biological assets		-	-
<b>IV. GROSS PROFIT (LOSS)</b>		-	-
V. Selling expenses		-	-
VI. General and administrative expenses		(427)	-
VII. Other operating results		-	-
VIII. Income from investments in the shares of parent, subsidiaries and associated entities		-	-
IX. Income from other long-term investments and loans		-	-
X. Other interest and similar income		-	-
XI. The impairment of the financial assets and short-term investments		-	-
XII. Interest and other similar expenses		-	-
<b>XIII. PROFIT (LOSS) BEFORE TAXATION</b>		(427)	-
XIV. Tax on profit		-	-
<b>XV. NET PROFIT (LOSS)</b>		(427)	-

Financial statements signed by electronic signature:

\_\_\_\_\_  
General Manager

\_\_\_\_\_  
Tomas Milašauskas

\_\_\_\_\_  
Representative of a company  
providing accounting services

\_\_\_\_\_  
Virginija Skirmantė